Skip to main content

Therapeutic targets for neuroblastomas.

Publication ,  Journal Article
Brodeur, GM; Iyer, R; Croucher, JL; Zhuang, T; Higashi, M; Kolla, V
Published in: Expert opinion on therapeutic targets
March 2014

Neuroblastoma (NB) is the most common and deadly solid tumor in children. Despite recent improvements, the long-term outlook for high-risk NB is still < 50%. Further, there is considerable short- and long-term toxicity. More effective, less toxic therapy is needed, and the development of targeted therapies offers great promise.Relevant literature was reviewed to identify current and future therapeutic targets that are critical to malignant transformation and progression of NB. The potential or actual NB therapeutic targets are classified into four categories: i) genes activated by amplification, mutation, translocation or autocrine overexpression; ii) genes inactivated by deletion, mutation or epigenetic silencing; iii) membrane-associated genes expressed on most NBs but few other tissues; or iv) common target genes relevant to NB as well as other tumors.Therapeutic approaches have been developed to some of these targets, but many remain untargeted at the present time. It is unlikely that single targeted agents will be sufficient for long-term cure, at least for high-risk NBs. The challenge will be how to integrate targeted agents with each other and with conventional therapy to enhance their efficacy, while simultaneously reducing systemic toxicity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert opinion on therapeutic targets

DOI

EISSN

1744-7631

ISSN

1472-8222

Publication Date

March 2014

Volume

18

Issue

3

Start / End Page

277 / 292

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neuroblastoma
  • Nervous System Neoplasms
  • Mutation
  • Humans
  • Gene Silencing
  • Epigenesis, Genetic
  • Animals
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 0801 Artificial Intelligence and Image Processing
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brodeur, G. M., Iyer, R., Croucher, J. L., Zhuang, T., Higashi, M., & Kolla, V. (2014). Therapeutic targets for neuroblastomas. Expert Opinion on Therapeutic Targets, 18(3), 277–292. https://doi.org/10.1517/14728222.2014.867946
Brodeur, Garrett M., Radhika Iyer, Jamie L. Croucher, Tiangang Zhuang, Mayumi Higashi, and Venkatadri Kolla. “Therapeutic targets for neuroblastomas.Expert Opinion on Therapeutic Targets 18, no. 3 (March 2014): 277–92. https://doi.org/10.1517/14728222.2014.867946.
Brodeur GM, Iyer R, Croucher JL, Zhuang T, Higashi M, Kolla V. Therapeutic targets for neuroblastomas. Expert opinion on therapeutic targets. 2014 Mar;18(3):277–92.
Brodeur, Garrett M., et al. “Therapeutic targets for neuroblastomas.Expert Opinion on Therapeutic Targets, vol. 18, no. 3, Mar. 2014, pp. 277–92. Epmc, doi:10.1517/14728222.2014.867946.
Brodeur GM, Iyer R, Croucher JL, Zhuang T, Higashi M, Kolla V. Therapeutic targets for neuroblastomas. Expert opinion on therapeutic targets. 2014 Mar;18(3):277–292.

Published In

Expert opinion on therapeutic targets

DOI

EISSN

1744-7631

ISSN

1472-8222

Publication Date

March 2014

Volume

18

Issue

3

Start / End Page

277 / 292

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neuroblastoma
  • Nervous System Neoplasms
  • Mutation
  • Humans
  • Gene Silencing
  • Epigenesis, Genetic
  • Animals
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 0801 Artificial Intelligence and Image Processing